How Will Payers Manage The High Cost Of Combinations Of New Oncology Agents, As Many Of These Therapies Become The Preferred Treatment Options To Optimize Patient Outcomes?
Paglia, R, Del Carlo, A, Schwartz, J, Carter, EA, Foy, C, Dyson, S, Areteou, TVolume:
21
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.04.250
Date:
May, 2018
File:
PDF, 94 KB
english, 2018
File converter
More search results
More benefits 
